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No more itch
Treatment of itch has not been as successful as the treat-
ment of pain, and chronic pruritus can be just as debilitating 
as chronic pain. Our inability to inhibit itch has been due, in 
part, to our lack of understanding of the underlying neuro-
modulatory mechanisms. In practice, menthol and other 
counterstimulatory agents provide almost instantaneous relief 
of itch, suggesting that crossmodal inhibition occurs centrally, 
perhaps within the spinal dorsal horn. Kardon and colleagues 
recently characterized B5-1 neurons, which correspond to 
specific neurochemically defined populations. These cells 
release κ-opioid dynorphin, which functions locally within the 
spinal cord to specifically reduce itch. Dynorphin, then, is a key 
neuromodulator of pruritus. Interestingly, menthol fails to inhibit 
itch in mice lacking these neurons, suggesting that B5-1 neurons 
may mediate inhibition of itch by chemical counterstimuli. 
These findings provide evidence that κ-opioids may be an 
effective therapy for treating a broad spectrum of chronic itch. 
(Neuron 82:573–86, 2014) Selected by E. Lerner
Getting on my nerves
Imiquimod induces inflammatory lesions that resemble psoriasis 
via a response that is mediated by IL-23. Interestingly, clinical 
reports and studies in mice have indicated that intralesionally 
administered anesthetics or surgical denervation abrogate 
sensation as well as inflammation. Riol-Blanco and colleagues 
recently employed the imiquimod mouse model to demonstrate 
that TRPV1+ nociceptive sensory neurons drive the inflam-
matory response in IL-23-mediated psoriasiform skin disease. 
Dermal dendritic cells were found to be the principal source 
of imiquimod-induced IL-23, and importantly, more than three 
quarters of these cells were in direct contact or close proximity 
to sensory neurons. Thus, dermal nociceptors induce nearby 
dermal dendritic cells to produce Il-23, which then stimulates 
γδ T cells to secrete IL-17F and IL-22, leading to recruitment 
of circulating neutrophils and monocytes and subsequent 
psoriasiform skin inflammation. These findings reveal new 
avenues for treatment of inflammatory skin diseases. (Nature 
510:157–61, 2014) Selected by E. Lerner
On a scale of seconds and days
Although atopic dermatitis and other allergic disease are 
common, the complexity and interplay of genetic and envi-
ronmental risk factors have hampered our understanding of 
the disease process. Epidermal barrier permeability is regulated 
by the growth and differentiation of different cell types on the 
order of hours to days, whereas the phenotype of each cell 
within the epithelium is regulated by local effectors via protein–
protein interaction networks on the order of seconds to min-
utes. Domínguez-Hüttinger and colleagues recently reported 
an ordinary differential equation model of epithelium function 
that reflects the regulatory interplay between the two different 
protective properties, which function on different time scales. 
This multiscale model predicts that the underlying risk factors 
for atopic dermatitis are predictable from the clinically observed 
dynamic response of the skin barrier to environmental chal-
lenges. This modeling approach allows for the bidirectional 
interplay between skin barrier dysfunction and aberrant inflam-
matory response and may contribute directly to development 
of patient-specific treatment of atopic diseases. (Interface Focus 
3:20120090, 2013) Selected by H. Williams
STING operation
Nucleic acid sensing is a hallmark of the innate immune 
response. Indeed, the mere presence of free cytosolic DNA 
serves as a molecular indicator of danger. Gehrke and colleagues 
recently found that oxidation-induced DNA structural changes 
confer resistance to exonuclease TREX1-mediated degrada-
tion, leading to accumulation of oxidized DNA in the cytosol. 
This DNA, which contains the most frequent natural oxidative 
base modification, 8-hydroxyguanosine, functioned as a potent 
agonist for the STING-dependent cytoplasmic DNA-sensing 
pathway. Such oxidation occurs following antimicrobial reactive 
oxygen production or absorption of UV light. Immune recogni-
tion of this UV-damaged self-DNA in the skin may contribute to 
UV hypersensitivity and development of lesions in sun-exposed 
skin in patients with the autoimmune disease cutaneous lupus 
erythematosus. Together, these findings indicate that oxidized 
DNA constitutes a prototypic damage-associated molecular pat-
tern involved in the TREX1- and STING-mediated pathway of 
cytosolic DNA sensing in the defense against pathogens and auto-
immunity. (Immunity 39:482–95, 2014) Selected by T. Schwarz
Rescuing research
Although the past half century has heralded significant scientific 
discoveries including the genetic code, genome structure, cell 
cycle, and cell-signaling pathways, a severe imbalance between 
the money available for research and the ever-growing scientific 
community in the United States has developed. In a recent per-
spective, Alberts and colleagues delineated this troubling situa-
tion and outlined some possible remedies. These authors propose 
that the underlying cause of this malaise is the longstanding, yet 
inaccurate, assumption that the biomedical research system will 
expand indefinitely. The following recommendations for change 
were made: predictable budgets for US funding agencies, altera-
tions in the workforce composition, funding for novel ground-
breaking work, improvements in the peer-review process, and 
changes in governmental policies that currently fuel unsustain-
able research growth. In any case, these points should ultimately 
spark future discussion and offer a mechanism for progress 
toward maximizing the contribution of the United States to the 
global biomedical research enterprise. (Proc Natl Acad Sci USA 
111:5773–77, 2014) Selected by L. GoldsmithJournal of Investigative Dermatology (2014) 134, 2063. doi:10.1038/jid.2014.237
